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Abstract:  13 
Most bacteria in nature exist in biofilms, which are inherently tolerant to antibiotics. There is 14 
currently very limited understanding about how biofilms evolve in response to sub-lethal 15 
concentrations of antimicrobials. In this study, we use a biofilm evolution model to study the 16 
effects of sub-inhibitory concentrations of three antibiotics on Salmonella Typhimurium 17 
biofilms. We show that biofilms rapidly evolve resistance to each antibiotic they are exposed 18 
to, demonstrating a strong selective pressure on biofilms from low antibiotic concentrations. 19 
Whilst all antibiotics tested select for clinical resistance, there is no common mechanism. 20 
Adaptation to antimicrobials however has a marked cost for other clinically important 21 
phenotypes including biofilm formation and virulence. Cefotaxime selects mutants with the 22 
greatest deficit in biofilm formation followed by azithromycin and then ciprofloxacin. 23 
Understanding the impacts of exposure of biofilms to antibiotics will help understand 24 
evolutionary trajectories and may help guide how best to use antibiotics in a biofilm context. 25 
Experimental evolution in combination with whole-genome sequencing, is a powerful tool for 26 





Antimicrobial resistance (AMR) is a complex problem and a major threat to human and 29 
animal health 1. Understanding how bacteria develop resistance to antibiotics is important to 30 
inform how antibiotics should be used to minimise selection of AMR. Much of our 31 
understanding of the mechanisms of antibiotic action and resistance comes from 32 
experiments in which bacteria have been grown in liquid culture before being exposed to 33 
antibiotics. Yet most bacteria in nature exist in biofilms; aggregated communities of cells 34 
encased in a matrix 2.  Biofilms represent a fundamentally different mode of life to planktonic 35 
cultures and studies have demonstrated extreme changes in gene and protein expression 36 
profiles from the same strains when grown in liquid or as a biofilm 3. Many infections include 37 
a biofilm component which makes the infection difficult to treat; common examples include 38 
infections on prosthetic or indwelling devices. Biofilms are typically more tolerant to 39 
antibiotics, compared to the corresponding strain in liquid culture. One theory explaining the 40 
resistance to antibiotics of biofilms is that cells within a biofilm are metabolically inactive, and 41 
a high proportion are dormant “persister” cells. In these dormant subpopulations, 42 
characterised by arrested macromolecular syntheses, the cellular targets which the 43 
antibiotics poison are often not essential, thus impeding bactericidal activity 4. Despite this 44 
reduced metabolic rate, biofilms have been shown to be able to adapt rapidly to changing 45 
conditions and rapid selection of mutants with improved biofilm fitness is observed when 46 
bacteria are introduced to a new niche 5–8.  47 
Selection of antibiotic resistant mutants is a classic example of natural selection 9, with initial 48 
studies of mechanisms of resistance exposing populations to very high concentrations of 49 
antibiotics and selecting for survivors. This identified ‘high-impact’ mutations that can confer 50 
a large phenotypic benefit and proved very useful for characterising cellular targets and 51 
primary resistance mechanisms. However, more recent work has found that repeated 52 
exposure to sub-inhibitory concentrations of antimicrobials can select for high level 53 




levels of antimicrobials are common. Importantly, this also allows epistatic interactions 55 
between multiple genes to be selected and for fitness costs arising from resistance 56 
mutations to be ameliorated by additional, compensatory mutations 12. 57 
The aim of this study was to use a laboratory evolution model as a tool for studying 58 
responses to sub-inhibitory concentrations of antibiotics. We employed an experimental 59 
biofilm evolution model and used Salmonella Typhimurium as a model biofilm-forming 60 
pathogen which we exposed to three clinically relevant antibiotics (azithromycin, cefotaxime 61 
and ciprofloxacin). Biofilms increase Salmonella’s chances of survival in hostile 62 
environments, providing resistance against antimicrobial agents. This is due to their unique 63 
structure and matrix composition ,comprising of curli, cellulose, flagella etc. 13. Recent 64 
evidence has suggested that controlling the level of biofilm formation by Salmonella impacts 65 
its virulence in vivo 14. 66 
In this study, we compared drug exposed biofilm lineages to non-exposed controls and 67 
planktonic lineages. We measured changes in antibiotic resistance, biofilm capacity and 68 
pathogenicity, and subsequently investigated drug-specific mechanisms of resistance using 69 
genome sequencing. We observed rapid adaptation to antibiotic pressure which often 70 
carried a major cost for biofilm formation. We finally explored the consequences of 71 
acquisition of antibiotic resistance on pathogenicity while investigating the stability of 72 





A biofilm evolution model to study responses to antimicrobial stresses 75 
With relatively little known about how biofilms respond to sub-lethal exposure to 76 
antimicrobials, we studied the responses of biofilms to antibiotics and compared the results 77 
to planktonic controls using a bead model 7. To establish Salmonella biofilms, we grew 78 
bacteria on glass beads in broth. The beads served as a substrate for biofilms to form on 79 
and as a biofilm transfer vehicle. With each transfer, bacteria from the biofilm community had 80 
to colonise the new beads and establish biofilms on their surface before being transferred 81 
again. This system allows longitudinal exposure of biofilms to stresses and captures all the 82 
major components of the biofilm lifecycle.  After each passage, cells from biofilms were 83 
harvested and populations as well as individual representative strains were recovered and 84 
phenotypically characterised. Strains that developed resistance or exhibited altered biofilm 85 
formation were selected for whole-genome-sequencing to identify genetic mechanisms 86 
potentially responsible for these phenotypes (Figure 1). 87 
Biofilms were grown, in the presence of three clinically important antibiotics of different 88 
classes for the treatment of Salmonellosis; azithromycin (a macrolide, targeting protein 89 
synthesis), cefotaxime (a cephalosporin targeting cell wall synthesis) and ciprofloxacin (a 90 
fluoroquinolone targeting DNA gyrase). We identified concentrations of each agent (10 91 
μg/mL azithromycin, 0.062 μg/mL of cefotaxime, and 0.015 μg/mL of ciprofloxacin) that 92 
reliably restricted planktonic growth rates to approximately 70% of that of unstressed control 93 
cultures. Whilst this reduced the growth rate in exposed cultures compared to untreated 94 
controls, the incubation for 72 hours allowed cultures to reach maximal growth. Analysis of 95 
numbers of cells recovered from biofilms exposed to each condition allowed us to estimate 96 
the impact of the drug exposures on the number of generations each experiment will have 97 
completed. We determined the minimum, maximum and average number of generations 98 
expected in each condition for 17 passage cycles (Supplementary figure 1). This showed 99 




azithromycin completed ~289 generations (range 235-321), biofilms exposed to cefotaxime 101 
completed ~264 generations (243-280) and biofilms exposed to ciprofloxacin completed~306 102 
generations (265-326) in this period. Only the cefotaxime exposure resulted in a statistically 103 
significant change in number of generations compared to control conditions. There were no 104 
significant differences in the number of cells per ml of planktonic culture after 72 hours in any 105 
of the conditions. These conditions were then used for evolution experiments following an 106 
approach which has proved tractable in our previous planktonic evolution experiments 15.  107 
We ran three separate evolution experiments, one for each antibiotic. Each experiment 108 
included eight lineages: four drug-exposed bead lineages, two drug-exposed planktonic 109 
cultures and two drug-free bead control lineages (Figure 1b). Evolved isolates were 110 
recovered after each passage and tested for their biofilm ability, morphology and antibiotic 111 
susceptibility. Analysis of the numbers of SNPs present in isolates from various conditions 112 
showed no difference between treated and untreated biofilms (untreated isolates had an 113 
average of 29 SNPs compared to the parental strain whereas isolates from treated biofilms 114 
had an average between 24 and 35 SNPs; Supplementary figure 2). This supports our 115 
estimation that similar numbers of generations were achieved in treated biofilms to controls. 116 
Model validation and response to antibiotics 117 
To determine the appropriate conditions for the evolution experiments, we measured biofilm 118 
formation by S. Typhimurium 14028S in lysogeny broth (without salt) after 24, 48, 72 and 96 119 
hours, at 25oC, 30oC, 37oC and 40oC respectively. Biofilm formation was determined by 120 
measuring cfu per bead (Figure 2, a). Over 72 hours the highest amount of biomass formed 121 
(~106 cfu/ bead) was after incubation at 25oC or 30oC; this was stable and consistent. 122 
Therefore, we ran the evolution experiments at 30oC with a passage period of 72 hours. 123 
To confirm the model selects for evolution of increased biofilm formation, we phenotyped 124 
isolated single cells from drug-free bead-control lineages. We observed an incremental 125 
increase in biofilm formation with colonies isolated from the drug-free control beads forming 126 




three times as much biomass over the course of the experiment  (Figure 2, b). This 128 
confirmed the model strongly selects for adaptation to produce biofilms with increased 129 
biomass over time in the absence of any stressor. No change in biofilm formation was seen 130 
in planktonic lineages after passage in drug-free media. Sequencing of isolated strains from 131 
biofilms adapted to produce more biofilm identified a missense substitution within CytR 132 
(Gly569Ser) in multiple independent lineages. Loss of CytR function is known to increase 133 
biofilm formation via increased CRP levels. 134 
To investigate whether mutations which alter biofilm formation over time had an effect on 135 
susceptibility to antimicrobials, we isolated multiple single strains from populations from each 136 
of three time points across the experiment (early, mid and late)  and measured the MICs of a 137 
panel of antimicrobials (azithromycin, cefotaxime, chloramphenicol, ciprofloxacin, 138 
kanamycin, nalidixic acid, tetracycline and triclosan). We also calculated the ‘resistance 139 
score’, which represents an additive value of all MICs determined for each strain and plotted 140 
it against time (Figure 2, c). The first observation we made was that the resistance score of 141 
unexposed biofilm lineages does not change over time despite the increase in biofilm 142 
formation. In fact, no correlation was observed between the two phenotypes (biofilm 143 
formation and resistance) in control lineages passaged in the absence of any antimicrobial 144 
exposure (Figure 2, d). 145 
Biofilms rapidly evolve and adapt in response to sub-inhibitory antibiotic 146 
concentrations   147 
To test the phenotypic responses of biofilms repeatedly exposed to non-lethal 148 
concentrations of the test antibiotics, we characterised single isolates from the different 149 
timepoints for susceptibility to eight clinically relevant antimicrobials, biofilm formation and 150 
colony morphology. Phenotypic results derived from single cell isolates from the biofilm 151 
lineages directly compared to the corresponding planktonic lineages run at the same time 152 
are presented in figure 3. Panels on the left show the phenotypes of strains isolated from 153 




results for the biofilm-isolated strains are presented. Biofilm formation for each strain was 155 
calculated by the Crystal violet assay (CV) (left-hand graph in each panel) and colony 156 
morphology was also visually observed on plates supplemented with Congo red dye (shown 157 
above each panel). MICs were calculated using the agar dilution method for three 158 
independent colonies and the results show the fold increase in MIC for each drug (compared 159 
against the parent strain) shown as stacked bars for all the antibiotics tested in figure 3 (bar 160 
charts at right hand side of each panel).  161 
Biofilms rapidly evolved resistance in response to all three antibiotics (Figure 3). The time 162 
taken to select for emergence of mutants resistant to the antibiotics was similar in most 163 
biofilm and planktonic lineages. Azithromycin selected mutants in a stepwise manner with 164 
emergence of a population with an 8-fold MIC increase, followed by selection of highly 165 
resistant populations with MICs of azithromycin 32 times higher than the parent strain. The 166 
resistance of the azithromycin-exposed lineages became evident at the earliest time point 167 
and was fixed by the mid-point of the experiment (Figure 3 a, b). Cefotaxime demonstrated a 168 
similar dynamic with both planktonic populations and biofilms exhibiting decreased 169 
susceptibility which was maintained until the end of the experiment although there was a 170 
reduction in MICs between the middle and late time points (Figure 3, c-d). Adaptation to 171 
ciprofloxacin resistance was selected by the middle of the experimental period and remained 172 
fixed up to the final timepoint in both biofilm and planktonic lineages (Figure 3 e, f). 173 
Ciprofloxacin exposed lineages demonstrated cross-resistance to nalidixic acid (a drug in the 174 
same class) but the MICs of other drugs were impacted less than for lineages exposed to 175 
azithromycin or cefotaxime. 176 
While the selection dynamics seemed similar between biofilm and planktonic lineages at first 177 
glance, analysis of the MICs of all the antibiotics tested, revealed significant differences in 178 
the outcomes between biofilm and planktonic conditions. For instance, whilst planktonic 179 
populations, exposed to cefotaxime, become mainly resistant to cefotaxime, cefotaxime-180 




This pattern was consistent between independent lineages. These observations show that 182 
whilst the biofilms develop resistance to the selective antibiotics in a similar timeframe to 183 
planktonic cultures some of the outcomes and underlying mechanisms are likely to be 184 
distinct. 185 
Development of resistance often carries a cost in biofilm formation 186 
While it is widely accepted that increased biomass and matrix production improves resilience 187 
of biofilms to antimicrobial stress, we observed that biofilm formation itself was heavily 188 
influenced by the selective antibiotic. For example, exposure to azithromycin selected 189 
resistance but strains under this selective pressure were severely constrained in adapting 190 
and forming better biofilms when compared to unexposed biofilms which produced much 191 
more biomass over time (Figure 3b). Cefotaxime had a strong negative effect on biofilm 192 
formation, with biofilms exposed to cefotaxime producing less biomass than the starting wild-193 
type strain and exhibiting a pale colony morphology on CR plates (Figure 3d). Ciprofloxacin 194 
had less impact on biofilm formation and biofilms exposed to this drug produced increased 195 
biomass over time, although to only half the level of the control biofilms. As expected, 196 
isolates from planktonic lineages did not form better biofilms over time. In fact, cefotaxime 197 
exposure again selected for weaker biofilms with a pale colony morphology on CR plates 198 
(Figure 3c). 199 
These data show that even low concentrations of antibiotics impose a strong selection for 200 
resistance to emerge in Salmonella biofilms, but that this carries a large cost to biofilm 201 
formation. This antibiotic pressure overrides the strong selection of the model for increased 202 
biofilm formation seen in the control lineages and the substitution within CytR seen in 203 
untreated lineages was not detected in any of the drug-exposed biofilms. 204 
Different antibiotics select for bespoke mechanisms of resistance 205 
To identify the mechanisms responsible for the phenotypes described above, we whole 206 




experiments and identified changes in each compared to the parent strain genome. We also 208 
used this data to infer the phylogeny of the mutants (from 63 isolates selected to represent 209 
the major phenotypes of interest and to cover different times in the exposure series for each 210 
drug) (Supplementary figure 3). The results showed that different antibiotics selected for 211 
mutants which followed distinct paths of adaptation and, for all antibiotics there was 212 
separation between biofilm (dark circles) and planktonic (light circles) lineages. With no 213 
common changes shared among the three drug exposures, it is unlikely that a universal or 214 
generic mechanism of resistance in biofilms or planktonic lineages exists.  215 
To identify mutations linked to the phenotypes observed, we calculated the average variant 216 
presence per environment (planktonic and biofilm) and per exposure (Figure 4). Presence of 217 
a variant in all isolates (from independent lineages) per condition was scored as 1 (black), 218 
whereas absence of a genomic change was scored as 0 (white). Intermediate values 219 
represent the fraction of isolates carrying the genetic change. 220 
Among the genetic changes identified, some were identified as being responsible for drug 221 
resistance, and were often shared between biofilms and planktonic cultures. For example, 222 
under azithromycin exposure, a SNP emerged in both conditions resulting in an arginine to 223 
glutamine substitution, at position 717 of the major efflux pump component AcrB. A 224 
substitution in a different position within AcrB (Gln176Lys) emerged only in planktonic 225 
cultures under cefotaxime selection. Several other substitutions within AcrB have been 226 
characterised in the past for their involvement in reduced drug susceptibility 16,17.  227 
Another target identified, previously linked to drug resistance was RamR, which is a 228 
transcriptional repressor of ramA, a global transcriptional activator that positively regulates 229 
the AcrAB-TolC pump production 18. Mutations within RamR emerged under azithromycin 230 
exposure. Substitution in position 194 (term194Tyr) of the same protein was seen in 231 
planktonic cultures and a substitution in position 18 (Thr18Pro) emerged in the biofilm 232 




Under cefotaxime exposure, mutations within the periplasmic protein EnvZ emerged in 234 
multiple locations within the protein and were unique for this condition. EnvZ is an 235 
osmolarity-sensor protein, attached to the inner membrane of the cell. It functions both as a 236 
histidine kinase and a phosphatase, exerting its activity by altering the phosphorylation 237 
levels of its cognate transcriptional regulator OmpR. OmpR, amongst other functions, is 238 
responsible for differential regulation of the expression of OmpC and OmpF, two principal 239 
outer-membrane porins 19,20, as well as curli biosynthesis through the csgD-csgBAC operon 240 
21.  241 
Under ciprofloxacin exposure, mutants resulting in substitutions within GyrA were observed, 242 
with multiple substitutions emerging at Ser83 in both biofilm and planktonic conditions. Ser83 243 
substitutions within GyrA are well characterised for roles in quinolone resistance 22–24.   244 
Increased biomass had a limited impact on resistance 245 
Control biofilms not exposed to drugs adapted and formed better biofilms over time (Figure 246 
2b). However, whilst this increase in biomass production was significant with adapted 247 
biofilms producing ~3X as much biomass as the parent strain, this did not result in reduced 248 
drug susceptibility (Figure 2 c,d). To further examine the relative impact of prior exposure to 249 
a specific drug versus biomass formation on survival to drugs in a biofilm we selected a set 250 
of four strains and examined their ability to survive exposure to ciprofloxacin when grown as 251 
a biofilm.  We compared: the parental strain; a planktonic isolate which had been repeatedly 252 
exposed to ciprofloxacin which demonstrated ciprofloxacin resistance but wild-type biomass 253 
production (Cip-plank-L-S1); a control biofilm-adapted isolate not exposed to any drug which 254 
demonstrated high biomass production (~6 X more than wild-type) and wild-type 255 
ciprofloxacin susceptibility (biofilm-control-L-S1); and a ciprofloxacin-exposed, biofilm 256 
adapted isolate which was ciprofloxacin resistant and also demonstrated some increased 257 
biomass (~3 X more than wild-type) production (Cip-biofilm-L-B-S3).  258 
These isolates were allowed to form biofilms on beads before being exposed to a range of 259 




the relative survival rate of cells within each biofilm (in relation to the corresponding 261 
untreated lineage) by counting viable cells from various adapted lineages and by live/ dead 262 
staining and microscopy. 263 
The results showed that neither being ciprofloxacin resistant, nor producing increased 264 
biomass alone allowed survival to high concentrations of the drug. Cells able to survive 265 
exposure to high levels of ciprofloxacin were only observed in the lineage which had 266 
previously been  exposed to ciprofloxacin in the biofilm context even though this strain had 267 
the same MIC of ciprofloxacin as the strain recovered from planktonic exposure to 268 
ciprofloxacin (Figure 5a). Although control biofilms made significantly more biomass than the 269 
drug-exposed biofilms, they only exhibited a mild increase in survival compared to the 270 
parental strain. Biofilms formed by the drug-exposed planktonic lineage (adapted and highly 271 
resistant to ciprofloxacin but with equivalent biofilm formation ability to the parent) also only 272 
had a mild increase in survival compared to WT biofilms. Only bacteria from the biofilm 273 
lineage exposed to ciprofloxacin exhibited a significant increase in survival. This data 274 
suggests that for optimum survival within a biofilm context neither acquisition of specific 275 
resistance to ciprofloxacin nor the ability to make improved biofilms are enough whereas 276 
conditional exposure to the drug results in best survival when challenged. These results 277 
were confirmed by fluorescence microscopy (Figure 5b) when biofilms of the same strains 278 
were grown on coverslips and exposed to equal amounts of ciprofloxacin.  279 
Development of drug resistance in biofilms impacts virulence 280 
To test whether drug adaptation influences pathogenicity, we selected isolates from different 281 
exposures and tested their virulence using the Galleria mellonella infection model (Figure 5c, 282 
bar chart). Larvae were injected with strains representing different biofilm and resistance 283 
phenotypes. Un-injected larvae as well as PBS controls were included and the wild type 284 
strain (14028S) was used as a reference. In parallel we measured biofilm formation and 285 
colony morphology for all cultures used to inoculate larvae using both the CV (Figure 5c, 286 




increased biofilm ability were the least infectious, whereas isolates with weaker biofilm 288 
phenotypes were more pathogenic. For example, biofilm-control-L-S1, which is a drug free 289 
control, biofilm-adapted strain, caused the least deaths with a 95% survival rate. In 290 
comparison, Cip-biofilm-M-B-S2, which is a drug-resistant but low-biofilm-forming strain, 291 
killed 50% of the larvae. Hence, adaptation to the drug exposure had no obvious advantage 292 
for pathogenicity. Our data suggests a link between pathogenicity and biofilm formation but 293 
no association to resistance. 294 
Resistance selected in biofilms is stable but costs to other phenotypes can be 295 
ameliorated by drug free passage 296 
To test the stability of the phenotypes obtained during the evolution experiments, we 297 
selected seven resistant strains selected by the previous antibiotic exposures with low and 298 
high biofilm forming abilities (see materials and methods) and put them through a 24-hour 299 
passage, accelerated biofilm evolution experiment (Figure 6, a-d). This experiment ran for 10 300 
days with passages every 24 hours without any antibiotics present, to test whether the 301 
resistance and biofilm patterns change over time without any selection. From each 302 
population, we isolated single strains and phenotyped them for their biofilm ability and their 303 
susceptibility against the same panel of antibiotics, as used previously. We calculated the 304 
average fold change in MIC per drug tested. In general, we observed no significant 305 
difference in drug susceptibility at the strains over time (Figure 6, a). However, their overall 306 
ability to form biofilms significantly improved (Figure 6, b). We also focused on individual 307 
strains with initially low biofilm ability and drug resistance (azi-biofilm-M-B-S2, cef-biofilm-L-308 
A-S1) and observed that stability of resistance was variable. In both cases, the biofilm 309 
formation of the strains improved over time. The MIC of azithromycin did not significantly 310 
change over time for the azithromycin resistant strain (Figure 6, c, orange line), whereas the 311 
initially cefotaxime resistant strain exhibited significantly greater susceptibility by the end of 312 





While it is known that biofilms are inherently highly tolerant to drug exposure 25–29, little work 315 
explores how biofilms evolve in response to antimicrobials. One recent report showed that 316 
Acinetobacter biofilms do adapt to sub-lethal exposure to ciprofloxacin and that mechanisms 317 
of resistance were distinct to those seen in planktonic controls 30,31. Another study showed 318 
that Acinetobacter and Pseudomonas biofilms positively respond to sub-inhibitory 319 
concentrations of the aminoglycoside tobramycin and identified parallel mechanisms of 320 
adaptation in both organisms 8.  321 
This study used laboratory evolution as a tool to describe adaptation of Salmonella in 322 
response to three different antibiotics, identified potential pathways of resistance and 323 
explored how the environment of growth determines pathways of adaptation and potential 324 
evolutionary trajectories. We demonstrated that Salmonella rapidly adapts to the biofilm 325 
model and forms improved biofilms over time.  Biofilms also rapidly evolved in response to 326 
sub-inhibitory exposures of antibiotics with different antibiotics selecting for drug-specific 327 
patterns of adaptation. This agrees with the recent work with Acinetobacter and 328 
Pseudomonas showing biofilms are very sensitive to low levels of antibiotics. The absence 329 
of a single, common response to the drugs tested suggests that there is not a generic 330 
antibiotic resistance mechanism in biofilms but instead adaptation depends on the nature of 331 
the specific stress. In line with this idea, although we showed that biofilms respond and 332 
adapt to antibiotics, this was not linked to biomass production. In fact, we identified clear 333 
trade-offs between drug resistance and biofilm formation. This pattern was not seen in the 334 
recent Acinetobacter and Pseudomonas work 8, suggesting species and drug specific 335 
differences in biofilm evolution pathways are important. Previous studies have associated 336 
exposure to sub-inhibitory concentrations of azithromycin and cefotaxime with selection of 337 
mutants with inhibited biofilm formation, although only planktonic cultures were exposed in 338 




acquired a clear advantage in the presence of the antibiotic, this comes with a cost and their 340 
ability to survive in the real world may be compromised as a result.  341 
One possible reason the biofilms exposed to drugs produced less biomass than controls 342 
could have been a lack of generations in the stressed lineages. However, we do not think 343 
this is a contributory factor for multiple reasons. Firstly, there was only a significant reduction 344 
in the total number of generations for biofilms exposed to cefotaxime (Supplementary figure 345 
1) whereas all drug exposures impaired biofilm formation. Secondly, even though the 346 
cefotaxime treatment resulted in less generations than the control, we remain confident that 347 
the smaller number of generations in this condition is not enough to explain the marked 348 
reduction in biofilm formation seen after cefotaxime exposure. For example, at the ‘late’ time 349 
point the cefotaxime lineages will have completed ~40 more generations than the control 350 
lineages have at the ‘middle’ time point, however at these corresponding points the 351 
cefotaxime exposed lineages produce less biomass whereas the controls produce 352 
significantly more biomass. Finally, the number of SNPs in different conditions was 353 
analysed, there was no difference between the conditions (Supplementary figure 2) so a lack 354 
of ‘mutational supply’ due to reduced number of generations is not likely to explain the 355 
impaired biofilm formation in all drug exposed lineages. 356 
To study the genetic basis for the phenotypes observed, we whole genome sequenced 357 
several strains based on their ability to form biofilms, their response to antimicrobials or a 358 
combination of the two. Some of the mutations we identified were linked to either the biofilm 359 
or the planktonic state. We also identified changes strongly associated with resistance in 360 
both environments. These mutations fall under common mechanisms of resistance affecting 361 
the balance between influx and efflux of drugs in and out of the bacterial cell, that can lead 362 
to not only susceptibility towards the stressor but also phenomena of multidrug resistance. 363 
All three of the drugs used are known efflux substrates and over-expression of efflux pumps 364 




It has been shown that altering efflux function in Salmonella can also result in reduced 366 
biofilm formation which may explain the trade-off between development of resistance and 367 
impaired biofilm formation 34. Mutations in efflux pumps and regulators were observed in 368 
both azithromycin and cefotaxime exposed lineages, where biofilm was most affected by 369 
development of resistance.  370 
Although high-level resistance to cefotaxime and azithromycin is often a result of acquisition 371 
of specific enzymes, in this closed system, acquisition of DNA is not possible, so cells are 372 
constrained to mutation of the core genome to generate resistant mutants. For instance, 373 
azithromycin selected for a SNP within AcrB (R717L), a major component of the MDR efflux 374 
pump AcrB-TolC and in RamR, which is a regulatory element of the pump. These mutations 375 
appeared in independent lineages and emerged in a stepwise manner over the course of the 376 
evolution experiment. The substitution identified in AcrB was in position 717 of the protein 377 
and was shared between planktonics and biofilms, whereas the RamR Thr18Pro was 378 
restricted to biofilms. The R717L AcrB substitution was recently linked to the emergence of 379 
azithromycin-resistant S. Paratyphi strain in a recent outbreak in Bangladesh 35. Other 380 
substitutions within AcrB have been identified in the past and have been predicted to change 381 
affinity for different drugs 16.  382 
Alteration of efflux function is a common mechanism of resistance,  and overproduction of 383 
the pump is a well-characterised mechanism of resistance in clinical isolates 36. It is likely 384 
that the mutation within RamR (Thr18Pro) is linked to the stepwise increase in MIC we 385 
observed for the strains exposed to azithromycin and substitutions within RamR including 386 
this residue have been characterised by previous studies, implicating them in drug 387 
resistance 18.  388 
Exposure to cefotaxime selected for mutations within EnvZ (R397H) as well as AcrB 389 
(Q176K). As shown before, alterations in AcrB’s structure can result in increased resistance 390 
to different drugs as a result of more efficient efflux 37. EnvZ on the other hand has been 391 




within EnvZ were only observed under cefotaxime exposure, with the same substitution 393 
emerging in multiple lineages in parallel (R397H). This implies a strong correlation of this 394 
substitution with the emergence of resistance in these strains. A recent study has shown a 395 
link between mutations in EnvZ under selection pressure with carbapenems and alterations 396 
in membrane permeability 38. We hypothesise therefore that this substitution within EnvZ 397 
may have a direct role in alterations of membrane permeability in these strains, which may 398 
lead to reduced susceptibility. Although the EnvZ mutation emerged in parallel in both the 399 
biofilm and planktonic environments, AcrB Q176Ksubstitution was only recovered in 400 
planktonic conditions. This may suggest different routes of adaptation between planktonics 401 
and biofilms to cefotaxime.  402 
Ciprofloxacin exposure selected for a wider variety of mutations with much more variation in 403 
phenotypes indicating multiple paths of evolution and resistance. The difference in the 404 
pattern of mutations selected between the drugs is likely to reflect the mechanisms of action 405 
and resistance; with multiple known chromosomal mechanisms of ciprofloxacin resistance 406 
(including target site changes, porin loss, efflux). 407 
To explore the trade-off between biofilm formation and resistance, we selected strains 408 
representing a variety of biofilm formation and resistance phenotypes and tested them for 409 
their ability to survive exposure to a range of ciprofloxacin concentrations. We observed that 410 
only biofilms which had been exposed to ciprofloxacin were significantly harder to kill than 411 
the parent strain. This reflects their possession of both a robust community structure and 412 
drug-specific resistance mutations that makes them fitter in the specific environment. Based 413 
on these results, we hypothesise that producing more biomass alone is not a sufficient 414 
solution to survive antibiotic exposure. Highly resistant biofilms are more likely to evolve from 415 
a combination of both structural and drug specific mechanisms. 416 
Biofilms play a crucial role in chronic infections and our observations suggested an obvious 417 
fitness advantage of adapted biofilms over unexposed biofilm populations in terms of drug 418 




different resistance and biofilm profiles, using the Galleria mellonella infection model. We 420 
observed that mutations that rendered the bacteria resistant to drugs had no significant 421 
impact on pathogenicity. However, the biofilm ability of the strains was negatively correlated 422 
with pathogenicity, with strains forming least biofilm being most virulent resulting in the 423 
lowest survival rates.  424 
Having characterised biofilm-related resistant phenotypes, we estimated their stability in the 425 
absence of drug selective pressure using an accelerated biofilm evolution experiment. 426 
Strains that had been exposed to ciprofloxacin and azithromycin maintained their resistance 427 
profiles over extended passaging but formed better biofilms. In contrast, cefotaxime exposed 428 
populations lost their acquired resistance after a few passages whilst they became better 429 
biofilm formers. This indicates that although stability of resistance is highly influenced by the 430 
nature of the antimicrobial stress, bacteria can quickly adapt to a more sessile, community-431 
orientated lifestyle in the absence of drug. Analysis of azithromycin-exposed populations 432 
which had improved their biofilm ability identified loss-of-function mutations in cyclic di-GMP 433 
phosphodiesterase, YjcC. Cyclic di-GMP is well known for its role in biofilm formation in 434 
several organisms including Salmonella, which harbors 12 proteins with GGDEF and 14 435 
proteins with EAL domains 39,40.  436 
In conclusion we demonstrate here that biofilms are highly sensitive to stress from low levels 437 
of antibiotics, rapidly adapt to drug pressure and that mechanisms of resistance can incur 438 
costs to other important phenotypes such as biofilm formation itself and virulence. We also 439 
demonstrate how laboratory evolution can be a powerful tool to understand the impacts of 440 
drug exposure on bacteria in different environmental niches. Future work will focus on the 441 
characterization of the mechanisms identified in this study for their role in resistance and 442 
biofilm formation. We believe that more studies on biofilm adaptation and evolution will help 443 
inform how best to use antimicrobials and predict how biofilms will respond to different 444 
stresses in the real world. 445 





Biofilm adaptation and evolution model 448 
Salmonella enterica serovar Typhimurium 14028S was used as the parent strain to initiate 449 
all biofilm experiments in this study. This strain has been used as a model for S. 450 
Typhimurium biofilm studies by many groups including our own and has a fully sequenced 451 
and annotated reference genome (Accession number: CP001363). To study adaptation and 452 
evolution of Salmonella biofilms, we adapted a model described by the Cooper group 7. 453 
Bacteria were grown on 6 mm soda lime glass beads (Sigma, Z265950-1EA) for 72 hours in 454 
Lysogeny Broth (LB) with no salt which allows a mature biofilm to form (Figure 1). They were 455 
incubated in glass universal tubes containing 5 mL of the medium in horizontal position, with 456 
mild rocking at 40 rpm, at 30 oC. For each passage, the beads were washed in PBS and 457 
transferred into fresh media with new sterile beads. The experiment was carried out in the 458 
presence of three clinically important antibiotics; azithromycin, cefotaxime and ciprofloxacin 459 
at a final concentration of 10 μg/mL, 0.062 μg/mL and 0.015 μg/mL respectively. Eight 460 
independent lineages were included per exposure: four drug-exposed biofilm lineages, two 461 
drug-exposed planktonic cultures and two unexposed, bead-only control lineages (Figure 1). 462 
In each tube, three initially sterile beads were used, one to be transferred to the next lineage, 463 
one to be stored, and one from which cells were recovered for phenotyping. For storage, one 464 
bead per passage was frozen in 20 % glycerol. For phenotyping, the cells were isolated from 465 
the beads by vortexing in PBS for 30 seconds and then grown overnight in 1 mL of LB broth, 466 
before being stored in chronological order in deep-well plates in glycerol. The experiments 467 
were completed after 17 passages for azithromycin and cefotaxime exposure and after 24 468 
passages for the ciprofloxacin exposure. The numbers of generations biofilms experienced 469 
were calculated using a previously described method (7) by: the number of passages x log2 470 
(the dilution factor). The number of cells per bead (dilution factor) was ~2.5 x 10-5 for drug 471 
free biofilms at the start of the experiments and ranged between ~5.2 x 10-4 to ~2.6 x 10-5 for 472 




biofilm generations after 17 passages of 305 for control lineages and between 264-306 for 474 
drug exposed lineages. Analysis of control and ciprofloxacin lineages over 70 generations 475 
showed a small increase in cell numbers over the period for both conditions (Supplementary 476 
figure 1). Populations from an early (first passage), middle (halfway point lineage) and late 477 
(final passage) time point were chosen for detailed study and from each, three single 478 
colonies were isolated, sub-cultured and stored in 20% glycerol. These isolates, and their 479 
parent populations were stored in deep-well 96-well plates and used for phenotyping by 480 
replicating the bacteria onto appropriate media to test for fitness, biofilm ability, morphology 481 
and susceptibility (replication used ‘QRep 96 Pin Replicators’, Molecular devices X5054). 482 
Figure 1 shows an overview of the experimental setup and phenotyping procedure. 483 
Model optimisation  484 
To determine the optimum culture conditions for achieving the greatest cell carriage of S. 485 
Typhimurium 14028S biofilms on the glass beads, biofilms were grown in 5 mL LB without 486 
salt on 6 mm glass beads at four temperatures: 25 °C, 30 °C, 37 °C and 40 °C. The cell 487 
counts on beads grown at each temperature was determined every 24 hours for a duration 488 
of 96 hours. Biofilms were washed in 1 mL PBS and harvested via vortexing for 30 seconds. 489 
The harvested cells were serially diluted in a microtiter tray containing 180 µL PBS and 5 µL 490 
was spotted onto a square LB agar plate. The number of colony forming units was calculated 491 
and the incubation conditions yielding the greatest number of cells was determined. 492 
Crystal violet assay (CV) 493 
To measure biofilm formation, selected strains were grown overnight in LB broth and then 494 
diluted into 200 μL of LB-NaCl to give an OD of 0.01 in microtiter plates. The plates were 495 
incubated at 30 oC for 48 hours, covered in gas-permeable seals before wells were emptied 496 
and vigorously rinsed with water before staining. For staining, 200 μL of 0.1% CV was added 497 
to each well and incubated for 15 minutes at room temperature. The crystal violet dye was 498 




dissolved in 70% ethanol and the absorbance was measured at 590 nm in a plate reader 500 
(FLUOStar Omega, BMG Labtech).  501 
Biofilm morphology 502 
To visually assess biofilms morphology, we replicated isolates stored in 96 deep-well plates 503 
on 1% agar LB-NaCl plates, supplemented with 40 μg/mL Congo red (CR) dye. The strains 504 
of interest were diluted to a final OD of 0.01 in a microtiter plate and were then printed on the 505 
Congo red plates using a 96-well plate pin replicator. The plates were incubated for 48 hours 506 
at 30 oC before being photographed to capture colony morphology.   507 
Antimicrobial susceptibility testing 508 
To determine the minimum inhibition concentrations of antimicrobials against strains of 509 
interest, we used the broth microdilution method 41 and the agar dilution method 42, following 510 
the EUCAST guidelines. In both cases, Mueller-Hinton broth or agar was used.  511 
Extraction of DNA 512 
To extract genomic DNA for sequencing, selected strains were grown O/N in a 96-deep-well 513 
plate in LB, at a final volume of 1.5 mL. Cells were recovered by centrifugation at 3,500 g 514 
and were resuspended in 100 μL of lysis buffer (5 μg/mL lysozyme, 0.1 mg/mL RNAse in 515 
Tris-EDTA, pH 8) per well. The resuspended cells were then transferred in a new semi-516 
skirted, low-bind PCR plate, secured with an adhesive seal and incubated at 37 oC, 550 g for 517 
25 minutes. 10 μL of a lysis additive buffer (5% SDS, 1 mg/mL proteinase K, 1 mg/mL 518 
RNAse in Tris-EDTA, pH 8) was added in each well and the plate was sealed with PCR strip 519 
lids before being incubated at 65 oC, 550 g for 25 minutes. The plate was briefly centrifuged 520 
and 100 μL were moved to a new PCR plate. For the DNA isolation, 50 μL of DNA-binding 521 
magnetic beads (KAPA Pure beads, Roche diagnostics) were added in each well and were 522 
incubated at room temperature for 5 minutes. The plate was then placed on a magnetic base 523 
and the supernatant was removed by pipetting. The beads were washed three times with 524 




minutes before eluting the DNA. For the DNA elution, the plate was removed from the 526 
magnetic apparatus and 50 μL of 10mM Tris-Cl, pH8.5 were added to each well. The beads 527 
were pulled using the magnetic apparatus and the isolated DNA was transferred to a new 528 
PCR plate. DNA concentration was determined using the Qubit ds DNA HS Assay kit 529 
(Q32851) following the manufacturer’s instructions.  530 
Whole Genome sequencing  531 
Genomic DNA was normalised to 0.5 ng/µL with 10mM Tris-HCl. 0.9 µL of TD Tagment DNA 532 
Buffer (Illumina Catalogue No. 15027866) was mixed with 0.09 µL TDE1, Tagment DNA 533 
Enzyme (Illumina Catalogue No. 15027865) and 2.01 µL PCR grade water in a master mix 534 
and 3ul added to a chilled 96 well plate. 2 µL of normalised DNA (1ng total) was mixed with 535 
the 3 µL of the tagmentation mix and heated to 55 C for 10 minutes in a PCR block. A PCR 536 
master mix was made up using 4 ul kapa2G buffer, 0.4 µL dNTP’s, 0.08 µL Polymerase and 537 
4.52 µL PCR grade water, contained in the Kap2G Robust PCR kit (Sigma Catalogue No. 538 
KK5005) per sample and 11 µL added to each well need to be used in a 96-well plate. 2 µL 539 
of each P7 and P5 of Nextera XT Index Kit v2 index primers (Illumina Catalogue No. FC-540 
131-2001 to 2004) were added to each well. Finally, the 5 µL Tagmentation mix was added 541 
and mixed. The PCR was run with 72 C for 3 minutes, 95 C for 1 minute, 14 cycles of 95 542 
C for 10 seconds, 55 C for 20 seconds and 72 C for 3 minutes. Following the PCR 543 
reaction, the libraries were quantified using the Quant-iT dsDNA Assay Kit, high sensitivity 544 
kit (Catalogue No. 10164582) and run on a FLUOstar Optima plate reader. Libraries were 545 
pooled following quantification in equal quantities. The final pool was double-spri size 546 
selected between 0.5 and 0.7X bead volumes using KAPA Pure Beads (Roche Catalogue 547 
No. 07983298001). The final pool was quantified on a Qubit 3.0 instrument and run on a 548 
High Sensitivity D1000 ScreenTape (Agilent Catalogue No. 5067-5579) using the Agilent 549 
Tapestation 4200 to calculate the final library pool molarity. The pool was run at a final 550 
concentration of 1.8 pM on an Illumina Nextseq500 instrument using a Mid Output Flowcell 551 




Illumina MiSeq instrument. Illumina recommended denaturation and loading 553 
recommendations which included a 1% PhiX spike in (PhiX Control v3 Illumina Catalogue 554 
FC-110-3001).  555 
Bioinformatics 556 
Sequence reads from the sequencer were uploaded on to virtual machines provided by the 557 
MRC CLIMB (Cloud Infrastructure for Microbial Bioinformatics) project using BaseMount 43. 558 
Quality filtering of the sequence reads was performed using Trimmomatic (version 3.5) with 559 
default parameters 44. Trimmomatic’s Illuminaclip function was used to remove the Illumina 560 
adapters. The trimmed reads were then assembled into contigs using SPAdes version 561 
3.11.1 using default parameters 45.  562 
To determine single nucleotide polymorphisms (SNPs) between the de novo assembled 563 
Salmonella genomes and the parent genome, Snippy version 3.1 was used using 564 
parameters recommended in (https://github.com/tseemann/snippy). The tool Snippy-core 565 
from the Snippy tool box was used to determine the core SNPs. The full genome alignment 566 
output by Snippy-core was used in subsequent phylogenetic analyses, after removal of the 567 
published reference sequence (accession number CP001363). All 4870267 sites were 568 
included in the analysis to avoid ascertainment bias 46.  Whole-genome-based phylogenetic 569 
trees were inferred from SNPs present in 63 sequenced isolates under the model HKY+G 570 
implemented in iq-tree 47. All trees were arbitrarily rooted at the cultivated parental sequence 571 
14028S for visualisation purposes, and were plotted with ggtree for R 48. Branch lengths are 572 
given in units of substitutions/site.  573 
To identify genomic changes potentially associated to the phenotypes observed, we 574 
subtracted changes present in our parent strain (14028S) and ended up with 392 variant 575 
locations, out of the 475 initial ones. The Glmnet R package 576 
(https://www.jstatsoft.org/article/view/v033i01) was then used for a regularised regression 577 
analysis: an elastic net regularization 49 on a logistic regression model was applied, where 578 




potential predictors. This analysis was conducted independently for each antibiotic exposure. 580 
The regularisation was based on a penalty parameter λ, controlling the selection of features 581 
and which was found by cross-validation. The elastic net is a combination of ridge regression 582 
and lasso regularisations, with weights of 7% lasso and 93% ridge regression penalties. 583 
These proportions were arbitrarily chosen to select variants with at least one non-zero 584 
coefficient (amongst the three independent analyses, one per antibiotic exposure). As a 585 
result of this analysis, 301 out of the 392 SNPs were selected. 586 
Viability of cells within biofilms 587 
To determine the viability of cells within a biofilm, two approaches were used. The first 588 
approach involved growing biofilms on glass beads for 72 hours. They were washed in PBS 589 
to remove planktonic cells and were then challenged with different concentrations of 590 
ciprofloxacin (0, 0.03, 0.3, 3 μg/mL) for 90 minutes. Beads were washed again in PBS to 591 
remove any antibiotic and transferred into 1 mL of PBS solution to an Eppendorf tube, where 592 
they were vigorously vortexed for 1 minute. The cells recovered in PBS were serial diluted 593 
and spotted onto LB plates for CFU counting the next day. For the second approach, we 594 
grew biofilms on glass slides for 72 hours. The slides were washed in PBS and were 595 
challenged with ciprofloxacin (3 μg/mL) for 90 minutes. They were washed in PBS and 596 
stained with a solution of 12 μM propidium iodide (PI) and 300 nM of SYTO 9 for 30 minutes. 597 
They were washed in PBS and soaked in 70% ethanol to kill the cells before they were 598 
transferred to a slide for microscopy. Fluorescence microscopy was performed in a Zeiss 599 
Axio Imager M2. 600 
Galleria Infection model 601 
To test the pathogenicity of different mutants, we used the Galleria mellonella larvae 602 
infection model. This model has previously been shown to be a simple, quick and ethical 603 
method to compare virulence between strains of Salmonella (24). Wax worms were obtained 604 
from livefoods.co.uk. Similarly, sized larvae with no signs of pupation or melanisation were 605 




S. Typhimurium 14028S in G. mellonella, which determined that an inoculation with 607 
approximately 20,000 CFU resulted in death of approximately half of 10 larvae after 72 608 
hours. Once this had been determined, overnight cultures of each strain were diluted in PBS 609 
to replicate this inoculum concentration and 10 μL of this were injected into the second 610 
hindmost left proleg of ten larvae. To check the concentration of each inoculum, 100 μL of 611 
each dilution were also plated onto LB agar and incubated overnight at 37°C. CFUs were 612 
counted the next day and the inoculum concentration was confirmed. Controls included in 613 
this experiment included larvae injected with PBS only and un-injected larvae. All larvae 614 
were incubated at 37 °C and were checked three times a day for 3 days to record the 615 
survival rate. The experiment was repeated on three independent occasions, with 10 larvae 616 
randomly allocated per strain in each experiment. Survival was calculated as the percentage 617 
of surviving larvae 48 hours after injection. 618 
Accelerated evolution experiments 619 
To test the phenotypic stability of strains recovered from the initial evolution experiments, we 620 
performed an accelerated evolution experiment using six strains representing a spectrum of 621 
biofilm forming capacities and drug resistance phenotypes (WT, control-biofilm-L-S1, azi-622 
biofilm-M-B-S2, azi-biofilm-M-B-S3, cef-biofilm-L-A-S1, cip-biofilm-M-B-S2, cip-biofilm-L-B-623 
S3). The strains were resuscitated from storage by a 24-hour incubation at 37 °C in LB 624 
broth. After incubation, 50 µL of broth was added to 5 mL of LB broth (without salt) 625 
containing three sterile glass beads and incubated for 24 hours at 30 °C, until a biofilm was 626 
formed. Each bead was then washed in 1 mL PBS to remove planktonic and loosely 627 
adherent cells. Two beads were stored in deep-well plates containing 20 % glycerol for 628 
archiving and phenotyping. The third bead was transferred to another tube of LB broth 629 
(without salt) containing three sterile glass beads and passaged. This was repeated for ten 630 
passages, storing beads at each timepoint. 631 
Upon completion of ten passages, populations were recovered from passage five, passage 632 




picked after streaking out each population on LB agar and incubating for 24 hours at 37 °C. 634 
Three colonies from each population were then sub cultured in LB broth. A population and 635 
three isolates from the start, middle and end of the passage series were isolated and 636 
phenotyped for each mutant. Biofilm formation was evaluated by assessing colony 637 
morphology on Congo Red plates and by measuring biomass using Crystal Violet assays as 638 
well as counting of numbers of cells from beads. The agar dilution methodology was used to 639 
assess the minimum inhibitory concentrations of antibiotics. The average of the fold MIC 640 
change per antibiotic for all strains was calculated and plotted against time. The average of 641 
biofilm formation, as determined by the crystal violet assay, was calculated for all the strains 642 
per timepoint. 643 
Statistical analysis 644 
Biofilm forming ability was compared using a regression analysis. Differences between 645 
strains over time were analysed using linear mixed models, with a random intercept of 646 
lineage where more than one lineage was included for each strain or condition.   647 
Surviving cell counts were compared between strains using a linear mixed model with a 648 
Poisson response, with random intercept of replicate for over-dispersion, fixed effects of 649 
exposure and the interaction between strain and exposure, and offset by the log of the 650 
average number of cells counted in the ‘unexposed’ condition for each strain.  Modelled 651 
means in each exposure were then normalised by the average number of cells across all 652 
unexposed conditions for plotting, such that the values shown represent the estimated 653 
proportion of cells that would survive each exposure for each strain. All error bars reflect 654 
estimates +/- one standard error.  655 
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Figure legends 809 
Figure 1: Biofilm adaptation model. a, Sterile beads were used for the establishment of 810 
biofilms. Biofilms formed on the beads were exposed to azithromycin, cefotaxime or 811 
ciprofloxacin b, eight independent lineages were included per experiment; two planktonic 812 
controls; two drug-free bead controls, and four biofilm test lineages. c, Cells were isolated 813 
every 72 hours after incubation at 30 oC and phenotyped using several assays d, Whole 814 
genome sequencing was used for the genetic characterization of selected strains. e, 815 
Confocal microscopy image (40X) of parental strain, 14028S biofilm formed on a glass bead 816 
after 72 hours. Cells were stained with SYTO9 before being visualized. Scale bar indicates 5 817 
µM. 818 
Figure 2: Biofilm model validation. a, Optimal conditions were determined by the strain’s 819 
capacity to form biofilms over time, at different temperatures. Maximum cell carriage was 820 
achieved at 72 h at either 25 oC or 30 oC. Dots indicate average from 4 replicates and error 821 
bars show standard error b, Biofilm formation in control lineages increased over time as 822 
seen by visualisation on Congo red-agar plates and by the Crystal Violet assay (OD:590nm). 823 
Each dot represents single cell strains isolated from different timepoints; experiments 824 
included three lineages each with three independent replicates. Error bars reflect estimated 825 
+/- one standard error. c, Control biofilms adapted without drug stress over time showed no 826 
changes in antimicrobial susceptibility (shown as ‘resistance score’; an additive value of all 827 
MICs determined for each strain). Data shown is from control lineages from a representative 828 
experiment. d, no correlation was observed between biomass formation (calculated using 829 
the CV assay) and resistance score. Data shown is aggregated from the control lineages 830 
from all three drug exposure experiments. 831 
Figure 3: Biofilms adapt to antibiotic stress, with diverse effects on biofilm formation.  832 
Planktonic and biofilm populations, exposed to azithromycin (a-b), cefotaxime (c-d) and 833 
ciprofloxacin (e-f) were isolated at different timepoints during the evolution experiment (early, 834 




biofilm lineages. Three single isolates from each condition and timepoint were tested for their 836 
biofilm ability (measured on three separate occasions, points show the mean for the 837 
technical replicates of each repeat) and antibiotic susceptibility. For reference, biofilm 838 
formation data from isolates from control experiments with no drug exposure is overlaid on 839 
the crystal violet graphs to allow comparison (grey points on each graph). Antibiotic 840 
susceptibility of a panel of different antimicrobials was determined and visualised by stacking 841 
the average MICs (from three independent isolates per condition) for each antibiotic. All 842 
lineages, exposed to azithromycin (a,b), developed resistance to azithromycin as well as 843 
decreased susceptibility to cefotaxime, chloramphenicol, ciprofloxacin, nalidixic acid, 844 
tetracycline and triclosan. Those isolated from biofilms were however compromised in biofilm 845 
formation (b). Planktonic lineages, exposed to cefotaxime, developed resistance only to 846 
cefotaxime whereas biofilms from the same exposure developed MDR (c,d). All lineages 847 
exposed to cefotaxime exhibited compromised biofilm formation with pale colonies on CR 848 
plates. All lineages exposed to ciprofloxacin (e,f) developed ciprofloxacin resistance and 849 
biofilm adaptation was delayed compared to the unexposed control lineages. 850 
Figure 4: Genetic variant distribution per genomic position 851 
For each group (combination of antibiotic exposure and biofilm formation), we calculated the 852 
average variant presence (SNPs, insertions, deletions, complex changes etc.) Absence of 853 
the variant in all sequenced isolates is scored as zero (white), indicating that no samples had 854 
the variant. Presence in all isolates is scored as one (black), indicating its presence in all 855 
sequenced isolates. Intermediate values represent the fraction of samples where the variant 856 
was observed. The three panels represent three continuous sections of the genome. 857 
Figure 5: Consequences of resistance 858 
a, Viability within a biofilm was tested using 72-hour biofilms treated with increasing 859 
concentrations of ciprofloxacin (0, 0.03, 0.3, 3 μg/mL). The strains tested were: cip-plank-L-860 
S1 (resistant; low-biofilm former), control-L-S1 (sensitive; good biofilm former) and cip-861 




were significantly harder to kill with ciprofloxacin. b, the same biofilms as in ‘a’ were pre-863 
treated with 3 μg/mL ciprofloxacin for 90 minutes, treated with live/dead stain and visualised. 864 
The different strains formed biofilms of variable density and an increased number of live cells 865 
was only observed in biofilms produced by the cip-biofilm-L-B-S3 strain. c, Pathogenicity 866 
(bars) was tested in the Galleria mellonella infection model. Each point indicates the average 867 
number of survivors from independent experiments and the bars show the average of these. 868 
The strains tested comprised different resistance phenotypes, with diverse biofilm abilities. 869 
WT and the unexposed control-L-S1 strain were used as references. Biofilm formation (lines) 870 
was measured by the CV assay and on CR plates. Survival was directly correlated with 871 
biofilm formation, with weak biofilm formers causing more deaths in this model regardless of 872 
antibiotic resistance. Scale bar indicates 5 µM. 873 
Figure 6: Stability of resistance 874 
a, Average fold change in MIC per antibiotic for seven strains was calculated after ten 24-875 
hour passages without any stressor present. For most antibiotics, resistance was stable 876 
throughout the accelerated evolution experiment except for cefotaxime. Dots show the 877 
average fold change in MIC derived from three isolates and error bars show +/- one 878 
standard error. b, Biofilm formation increased for most of the tested strains, by the end of the 879 
experiment.  Points represent modelled means in each exposure that represent the 880 
estimated proportion of cells present at each time point for each strain.  c, Individual 881 
example of an azithromycin resistant strain, which adapted and formed better biofilm over 882 
time without losing resistance to azithromycin. Pink line shows the changes in azithromycin 883 
MIC over time (line graph, left axis). Bars (bar chart, right axis) show the average biofilm 884 
formation from three replicates. Error bars indicate standard deviation   d, Individual example 885 
of a cefotaxime resistant strain, which adapted to forming better biofilm but lost the 886 
resistance to cefotaxime. Purple line shows the changes in cefotaxime MIC over time (line 887 
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